Market Overview:
The global dolutegravir and its combination drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of HIV/AIDS, rising demand for better treatment options, and the launch of new combination drugs. Based on type, the global dolutegravir and its combination drug market can be segmented into dolutegravir, abacavir/dolutegravir/lamivudine, and dolutegravir/rilpivirine. Dolutegravir is expected to account for the largest share of this market in 2018. Based on application, this market can be segmented into hospital, clinic, drug center, and other applications. Hospital is expected to account for the largest share of this market in 2018. Geographically, this market can be segmented into North America,, Latin America,, Europe,, Asia Pacific,,and Middle East & Africa,.
Product Definition:
Dolutegravir (DTG) is a drug used in the treatment of HIV-1 infection. It is a integrase inhibitor that blocks the viral enzyme integrase, which is essential for HIV replication. DTG is taken as a single tablet once daily and has few side effects. When combined with other antiretroviral drugs, DTG has been shown to be highly effective in suppressing HIV replication and preventing AIDS-related illnesses.
Dolutegravir:
Dolutegravir is a medication used to treat HIV-1 infection and aids in the prevention of viral transmission. It is also used as an antiretroviral agent in combination with other drugs. Dolutegravir was approved by the U.S Food and Drug Administration (FDA) for use as a single drug therapy, under its brand name, Duetact, in July 2003.
Abacavir/Dolutegravir/Lamivudine:
Abacavir/Dolutegravir/Lamivudine is an antiviral medication used for the treatment of HIV-1 infection and other retrovirus infections. It is part of a group of drugs known as reverse transcriptase inhibitors. The drug was approved by the U.
Application Insights:
The other application segment includes the use ofolutegravir and its combination drug for treatment of HIV infection in children. The use of Dolutegravir has been approved by the U.S FDA under accelerated approval process (PAA) for patients infected with HIV-1 who have no antiretroviral-resistant virus and are candidates for initial therapy.
Furthermore, Dolutegravir is also available as a generic medicine which can be purchased from pharmacies without a prescription. Lamivudine/Dolutegravir/Rilpivirin is an effective combination therapy used to treat chronic hepatitis B infection caused by HBV which has been approved by the U.S FDA under priority review program as well as section 505(o)of the FD&C Act).
Regional Analysis:
North America is expected to be the largest regional market over the forecast period owing to high awareness levels and availability of branded drugs. The region accounted for a revenue share of more than 60% in 2017, which is anticipated to decline over the forecast period due to launch of generic versions by manufacturers such as Gilead Sciences, Inc.; Cipla Inc.; and F. Hoffmann-La Roche AG & Co., Ltd. In addition, increasing number of treatment options available for HIV patients in U.S., coupled with rising prevalence rate will drive this regional market further.
Asia Pacific is estimated to be one of the fastest growing regions during the forecast years due its large population base suffering from HIV/AIDS and low cost associated with clinical trials pertaining drug development programs against diseases prevalent in this region; thus making it attractive for global players operating in other regions looking for lucrative opportunities at lower costs compared with developed economies globally (UNAIDS 2013).
Growth Factors:
- Increasing incidence of HIV/AIDS: The global prevalence of HIV is currently estimated at around 34 million people, and it is projected to grow to more than 45 million by 2020. This will create a large pool of patients who will require treatment, thereby driving the demand for Dolutegravir and Its Combination Drug market.
- Rising awareness about HIV/AIDS: There has been a significant increase in the awareness about HIV over the past few years, which is likely to drive the demand for Dolutegravir and Its Combination Drug market in the coming years.
- Technological advancements: The development of new and innovative drugs for the treatment of HIV/AIDS is expected to spur growth in Dolutegravir and Its Combination Drug market over the next few years.
- Growing number of partnerships between pharmaceutical companies: The growing number of partnerships between pharmaceutical companies is expected to result in increased competition within this market, which will ultimately benefit consumers by driving down prices and encouraging innovation.
Scope Of The Report
Report Attributes
Report Details
Report Title
Dolutegravir and Its Combination Drug Market Research Report
By Type
Dolutegravir, Abacavir/Dolutegravir/Lamivudine, Dolutegravir/Rilpivirine
By Application
Hospital, Clinic, Drug Center, Other
By Companies
ViiV Healthcare (GSK), Adcock Ingram Limited, Aurobindo Pharma, Cipla, Emcure Pharmaceuticals, LAURUS Labs, Mylan, Ranbaxy Pharmaceuticals, Shanghai Desano Pharmaceuticals, JNJ
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
156
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Dolutegravir and Its Combination Drug Market Report Segments:
The global Dolutegravir and Its Combination Drug market is segmented on the basis of:
Types
Dolutegravir, Abacavir/Dolutegravir/Lamivudine, Dolutegravir/Rilpivirine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drug Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ViiV Healthcare (GSK)
- Adcock Ingram Limited
- Aurobindo Pharma
- Cipla
- Emcure Pharmaceuticals
- LAURUS Labs
- Mylan
- Ranbaxy Pharmaceuticals
- Shanghai Desano Pharmaceuticals
- JNJ
Highlights of The Dolutegravir and Its Combination Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Dolutegravir
- Abacavir/Dolutegravir/Lamivudine
- Dolutegravir/Rilpivirine
- By Application:
- Hospital
- Clinic
- Drug Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dolutegravir and Its Combination Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dolutegravir is a drug used to treat HIV. It is combined with other drugs to help the body fight the virus.
Some of the major players in the dolutegravir and its combination drug market are ViiV Healthcare (GSK), Adcock Ingram Limited, Aurobindo Pharma, Cipla, Emcure Pharmaceuticals, LAURUS Labs, Mylan, Ranbaxy Pharmaceuticals, Shanghai Desano Pharmaceuticals, JNJ.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dolutegravir and Its Combination Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dolutegravir and Its Combination Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dolutegravir and Its Combination Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dolutegravir and Its Combination Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dolutegravir and Its Combination Drug Market Size & Forecast, 2018-2028
4.5.1 Dolutegravir and Its Combination Drug Market Size and Y-o-Y Growth
4.5.2 Dolutegravir and Its Combination Drug Market Absolute $ Opportunity
Chapter 5 Global Dolutegravir and Its Combination Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Dolutegravir and Its Combination Drug Market Size Forecast by Type
5.2.1 Dolutegravir
5.2.2 Abacavir/Dolutegravir/Lamivudine
5.2.3 Dolutegravir/Rilpivirine
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Dolutegravir and Its Combination Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Dolutegravir and Its Combination Drug Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Drug Center
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dolutegravir and Its Combination Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dolutegravir and Its Combination Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Dolutegravir and Its Combination Drug Analysis and Forecast
9.1 Introduction
9.2 North America Dolutegravir and Its Combination Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Dolutegravir and Its Combination Drug Market Size Forecast by Type
9.6.1 Dolutegravir
9.6.2 Abacavir/Dolutegravir/Lamivudine
9.6.3 Dolutegravir/Rilpivirine
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Dolutegravir and Its Combination Drug Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Drug Center
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Dolutegravir and Its Combination Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Dolutegravir and Its Combination Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Dolutegravir and Its Combination Drug Market Size Forecast by Type
10.6.1 Dolutegravir
10.6.2 Abacavir/Dolutegravir/Lamivudine
10.6.3 Dolutegravir/Rilpivirine
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Dolutegravir and Its Combination Drug Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Drug Center
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Dolutegravir and Its Combination Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Dolutegravir and Its Combination Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Dolutegravir and Its Combination Drug Market Size Forecast by Type
11.6.1 Dolutegravir
11.6.2 Abacavir/Dolutegravir/Lamivudine
11.6.3 Dolutegravir/Rilpivirine
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Dolutegravir and Its Combination Drug Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Drug Center
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Dolutegravir and Its Combination Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Dolutegravir and Its Combination Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Dolutegravir and Its Combination Drug Market Size Forecast by Type
12.6.1 Dolutegravir
12.6.2 Abacavir/Dolutegravir/Lamivudine
12.6.3 Dolutegravir/Rilpivirine
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Dolutegravir and Its Combination Drug Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Drug Center
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Dolutegravir and Its Combination Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Dolutegravir and Its Combination Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Dolutegravir and Its Combination Drug Market Size Forecast by Type
13.6.1 Dolutegravir
13.6.2 Abacavir/Dolutegravir/Lamivudine
13.6.3 Dolutegravir/Rilpivirine
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Dolutegravir and Its Combination Drug Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Drug Center
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dolutegravir and Its Combination Drug Market: Competitive Dashboard
14.2 Global Dolutegravir and Its Combination Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 ViiV Healthcare (GSK)
14.3.2 Adcock Ingram Limited
14.3.3 Aurobindo Pharma
14.3.4 Cipla
14.3.5 Emcure Pharmaceuticals
14.3.6 LAURUS Labs
14.3.7 Mylan
14.3.8 Ranbaxy Pharmaceuticals
14.3.9 Shanghai Desano Pharmaceuticals
14.3.10 JNJ
